LongeVC has invested in psychedelics startup Freedom Biosciences which is pioneering the use of ketamine and other compounds in next-generation treatments.
Reset Mind Sciences, a wholly-owned subsidiary of Little Green Pharma, has received Human Research Ethics Committee (HREC) approval for a trial investigating psilocybin-assisted psychotherapy for the...
Awakn Life Sciences has announced that Awakn Clinics Trondheim is now open and that it has initiated a feasibility study of MDMA leveraging Catalent’s proprietary Zydis...
In what marks an important development for Europe, a number of EU bodies have published a joint commentary in the world-leading medical journal, The Lancet, acknowledging...
For the next two weeks, a digital poster campaign will be featured in London asking the UK public “Could magic mushrooms be medicine?”.
Researchers from The University of Queensland have discovered the active compound from Hericium erinaceus – otherwise known as Lion’s mane – that boosts nerve growth and...
Tadeusz Hawrot, Founder and Executive Director of the Psychedelic Access and Research European Alliance (PAREA), speaks to Psychedelic Health about how the organisation plans to campaign...
COMPASS Pathways is recruiting participants for its trial investigating the safety and tolerability of its psilocybin formula – COMP360 – for post-traumatic stress disorder (PTSD).
Optimi Health has submitted an application to carry out a Phase I clinical trial investigating the safety of the combinatory use of psilocybin and MDMA in...
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Awakn Life Sciences an Innovation Passport for its proprietary ketamine-assisted therapy for the treatment of...